Osteoporosis after renal transplantation
- 11 November 2014
- journal article
- review article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 47 (3) , 503-511
Abstract
Bone loss and fracture are serious sequelae of kidney transplantation, associated with morbidity, mortality and high economic costs. The pathogenesis of post-transplantation bone loss is multifactorial and complex. Pre-existing bone mineral disease is responsible for a significant part, but it is aggravated by risk factors emerging after renal transplantation with immunosuppressive agents being one of the key contributors. The decrease in bone mass is particularly prominent during the first 6–12 months after transplantation, continuing at a lower rate thereafter. Bone mineral density measurements do not predict bone histology and bone biopsy findings reveal heterogeneous lesions, which vary according to time after transplantation. Currently, vitamin D and bisphosphonates are the most extensively tested therapeutic agents against this accelerated bone loss in renal transplant recipients. Both of these agents have proven effective, but there is no evidence that they decrease fracture risk. More studies are needed to examine the complex pathophysiologic mechanisms implicated in this population, as well as the effects of different therapeutic interventions on bone disorders after kidney transplantation.Keywords
This publication has 86 references indexed in Scilit:
- A 1-Year Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ibandronate on Bone Loss Following Renal TransplantationAmerican Journal of Transplantation, 2012
- Teriparatide Efficacy in the Treatment of Severe Hypocalcemia After Kidney Transplantation in Parathyroidectomized Patients: A Series of Five Case ReportsTransplantation, 2011
- Open-Label Trial: Effect of Weekly Risedronate Immediately After Transplantation in Kidney RecipientsTransplantation, 2010
- Cinacalcet Decreases Bone Formation Rate in Hypercalcemic Hyperparathyroidism after Kidney TransplantationAmerican Journal of Nephrology, 2010
- Bisphosphonates and Bone Fractures in Long-term Kidney Transplant RecipientsTransplantation, 2008
- Teriparatide or Alendronate in Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 2007
- Low‐Turnover Bone Disease in Hypercalcemic Hyperparathyroidism After Kidney TransplantationAmerican Journal of Transplantation, 2007
- Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3‐E1 cells and primary mouse bone marrow stromal cellsJournal of Cellular Biochemistry, 2007
- Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclastsBone, 2004
- Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in ratsCalcified Tissue International, 1993